Skip to main content
. 2010 Sep 14;68(1):69–77. doi: 10.1007/s00280-010-1431-9

Fig. 1.

Fig. 1

Maximum percent change from baseline in sum of longest diameters (SLD) of target lesions per RECIST and independent review in patients evaluable for response by RECIST or Choi criteria. Not shown: n = 1 progressive disease (new lesion; SLD unavailable). Not included: 18 patients (from the per-protocol set) without tumor response information (SLD measured prior to week 8). Changes in SLD > 30% shown as stable disease represent unconfirmed PRs